Eleftherios (Terry) Mamounas, MD, MPH, FACS, provides an update on genomic expression panels for chemotherapy decision-making in early-stage breast cancer. Recurrence scores were used to predict benefit in the RxPONDER trial, the MINDACT trial, and the ADAPT trial. RSClin has been developed and validated as prognostic and predictive of absolute chemotherapy benefit.